Technology forecast: advanced therapies in late clinical research, EMA approval or clinical application via hospital exemption

Background: The umbrella term ATMPs (Advanced Therapy Medicinal Products) comprises cell therapies, gene therapeutics and tissue engineered products. After implementation of the Regulation 1394/2007, only a couple of products have obtained a centralized European marketing authorisation. Objectives:...

Descripción completa

Detalles Bibliográficos
Autores principales: Eder, Claudia, Wild, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Routledge 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493298/
https://www.ncbi.nlm.nih.gov/pubmed/31069029
http://dx.doi.org/10.1080/20016689.2019.1600939

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493298/
https://www.ncbi.nlm.nih.gov/pubmed/31069029
http://dx.doi.org/10.1080/20016689.2019.1600939

Ejemplares similares